Lu-177

DRUG2 trials

Sponsors

Providence Health & Services, M.D. Anderson Cancer Center

Conditions

Lu-177 PSMANeuroendocrine Tumors

Phase 1

Study of Cabozantinib With Lu-177 in Patients With Somatostatin Receptor 2 Positive Neuroendocrine Tumors

Active, not recruitingNCT05249114

Providence Health & ServicesNeuroendocrine Tumors

Start: 2022-12-28End: 2026-12-31Updated: 2025-03-10

Unknown Phase

Evaluation of Targeted Radionuclide Therapy of Lu-177 PSMA in Patients With Compromised Renal and/or Bone Marrow Function

RecruitingNCT07169825

M.D. Anderson Cancer CenterLu-177 PSMA

Start: 2026-03-30End: 2028-09-01Target: 25Updated: 2026-04-02